AbbVie (NYSE: ABBV) has extended an agreement with the University of Chicago related to collaborative preclinical oncology research.
The North Chicago, Illinois–based company and the university are working together on research involving biomarkers and therapeutic applications related to existing AbbVie programs.
In the past, the organizations have also explored new drug delivery methods to improve the immune system’s ability to fight tumors. Their partnership has also focused on testing 3D screening methodologies for selecting promising therapeutic molecules.
Get the full story from our sister site, Drug Discovery & Development.
